ACE, Polyclonal Antibody

ACE; DCP; DCP1; Angiotensin-converting enzyme; Dipeptidyl carboxypeptidase I; Kininase II; CD_antigen - CD143; Angiotensin-converting enzyme; soluble form

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

IgG

Rabbit

This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

100 ul of antibody in PBS with 0.09% (W/V) sodium azide
Appearance: Colorless liquid

At -20 degree C
Shelf Life: 12 months

Small volumes of anti-ACE antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Polyclonal Antibody to detect ACE in human and mouse samples

Background: Angiotensin-converting enzyme (ACE) is a carboxy-terminal dipeptidyl exo-peptidase that converts Angiotensin I to the potent vasopressive hormone, Angiotensin II. There are two isoforms of ACE, the pulmonary ACEP and the testicular ACET. ACEP is a glycoprotein expressed in vascular endothelial cells of the lung, liver, adrenal cortex, pancreas, kidney and spleen. The ACET isoform is expressed exclusively in ***** testis by developing sperm cells, specifically, late pachytene spermatocytes. Additionally, ACE inactivates bradykinin, a vasodepressor peptide, and is involved in fluid/electrolyte homeostasis. Although it bears significant sequence homology to ACE, ACE2 shows a more restricted pattern of expression. ACE is expressed ubiquitously throughout the vasculature while ACE2 is expressed only in cardiac, renal and testicular cells.

Antibodies & Supporting Tools; Antibodies for Alzheimer's Research (NEW)Antibodies & Supporting Tools; Primary Antibodies (A-Z)

Western Blot (WB)

Western blot: 1:1000

78,694 Da

angiotensin I converting enzyme

angiotensin-converting enzyme

Angiotensin-converting enzyme

DCP; DCP1; ACE  [Similar Products]

ACE_HUMAN

This gene encodes an enzyme involved in catalyzing the conversion of angiotensin I into a physiologically active peptide angiotensin II. Angiotensin II is a potent vasopressor and aldosterone-stimulating peptide that controls blood pressure and fluid-electrolyte balance. This enzyme plays a key role in the renin-angiotensin system. Many studies have associated the presence or absence of a 287 bp Alu repeat element in this gene with the levels of circulating enzyme or cardiovascular pathophysiologies. Multiple alternatively spliced transcript variants encoding different isoforms have been identified, and two most abundant spliced variants encode the somatic form and the testicular form, respectively, that are equally active. [provided by RefSeq, May 2010]

ACE: Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. Genetic variations in ACE may be a cause of susceptibility to ischemic stroke (ISCHSTR); also known as cerebrovascular accident or cerebral infarction. A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. Ischemic strokes, resulting from vascular occlusion, is considered to be a highly complex disease consisting of a group of heterogeneous disorders with multiple genetic and environmental risk factors. Defects in ACE are a cause of renal tubular dysgenesis (RTD). RTD is an autosomal recessive severe disorder of renal tubular development characterized by persistent fetal anuria and perinatal death, probably due to pulmonary hypoplasia from early-onset oligohydramnios (the Potter phenotype). Genetic variations in ACE are associated with susceptibility to microvascular complications of diabetes type 3 (MVCD3). These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new- onset blindness among diabetic *****s. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. Defects in ACE are a cause of susceptibility to intracerebral hemorrhage (ICH). A pathological condition characterized by bleeding into one or both cerebral hemispheres including the basal ganglia and the cerebral cortex. It is often associated with hypertension and craniocerebral trauma. Intracerebral bleeding is a common cause of stroke. Belongs to the peptidase M2 family. 4 isoforms of the human protein are produced by alternative splicing.

Protein type: Membrane protein, integral; EC 3.4.15.1; Protease

Chromosomal Location of Human Ortholog: 17q23.3

Cellular Component: extracellular space; lysosome; extracellular region; integral to membrane; plasma membrane; endosome; external side of plasma membrane

Molecular Function: peptidyl-dipeptidase activity; tripeptidyl-peptidase activity; protein binding; zinc ion binding; metallopeptidase activity; carboxypeptidase activity; mitogen-activated protein kinase kinase binding; endopeptidase activity; bradykinin receptor binding; exopeptidase activity; mitogen-activated protein kinase binding; drug binding; chloride ion binding; actin binding

Biological Process: mononuclear cell proliferation; regulation of vasodilation; neutrophil mediated immunity; angiotensin mediated regulation of renal output; regulation of angiotensin metabolic process; angiotensin maturation; proteolysis; arachidonic acid secretion; regulation of systemic arterial blood pressure by renin-angiotensin; antigen processing and presentation of peptide antigen via MHC class I; cellular protein metabolic process; regulation of smooth muscle cell migration; heart contraction; regulation of blood pressure; beta-amyloid metabolic process; peptide catabolic process; regulation of vasoconstriction; angiotensin catabolic process in blood; blood vessel remodeling; spermatogenesis; hormone catabolic process; kidney development

Disease: Microvascular Complications Of Diabetes, Susceptibility To, 3; Renal Tubular Dysgenesis; Alzheimer Disease; Hemorrhage, Intracerebral, Susceptibility To

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.